Order byBest matchMost fresh

Hims, Eli Lilly and weight loss

Digest more
Top News
Impacts
Fierce Healthcare |
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss plat...
Wall Street Journal |
The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.

Read more on News Digest

DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform (April 1)
Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro — and generics of Novo's diabetes drug,
Eli Lilly weight loss therapy added to Hims & Hers platform (update)
Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy tirzepatide for sale on its platform.
Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Eli Lilly says company has no affiliation with Hims & Hers
In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be
Modern Healthcare1d
Eli Lilly denies affiliation with Hims & Hers
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.
Physician's Weekly11h
Zepbound Now Available Through Hims AND Hers
The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform. The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide,
‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company's prospects.
Eli Lilly is coming after makers of copycat versions of Zepbound
Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.
Feedback